期刊文献+

^(177)Lu-DTPA-BIS-BIOTIN的制备及正常鼠体内生物分布 被引量:1

Preparation of ^(177)Lu-DTPA-BIS-BIOTIN and Biodistribution Evaluation in Normal Mice
下载PDF
导出
摘要 研究了DTPA-BIS-BIOTIN的177Lu标记方法,优化了标记条件,并进行了标记物在正常小鼠体内分布实验。在最佳标记条件下(DTPA-BIS-BIOTIN 25μg,标记介质pH=4.5,80℃反应20 min),177Lu-DTPA-BIS-BIOTIN标记率大于99.0%,室温下放置96 h,标记物体外稳定性良好。正常小鼠体内分布实验结果表明,177Lu-DTPA-BIS-BIOTIN在血液中清除快,主要浓集于肝、脾和肾,经肾脏排泄。本研究为进一步采用177Lu-DTPA-BIS-BIOTIN进行肿瘤预定位显像及治疗研究提供了实验基础。 The labeling method for 177Lu-DTPA-BIS-BIOTIN was established,and the biodistribution of 177Lu-DTPA-BIS-BIOTIN in normal mice was carried out as well.Under the optimal experimental condition(DTPA-BIS-BIOTIN 25 μg,pH=4.5 reacting at 80 ℃ for 20 min),the labeling yield of 177Lu-DTPA-BIS-BIOTIN is more than 99.0%.177Lu-DTPA-BIS-BIOTIN shows pretty good in vitro stability.The biodistribution of 177Lu-DTPA-BIS-BIOTIN in normal mice shows a rapid blood clearance.The uptake of 177Lu-DTPA-BIS-BIOTIN is mainly accumulated in liver,spleen and kidney.177Lu-DTPA-BIS-BIOTIN is excreted by kidney.The results provide the basis for further study on 177Lu-DTPA-BIS-BIOTIN used in pretargeted radioimage and radiotherapy of cancer.
出处 《核化学与放射化学》 CAS CSCD 北大核心 2010年第3期184-188,共5页 Journal of Nuclear and Radiochemistry
基金 国家自然科学基金资助项目(30670584)
关键词 177Lu DTPA-BIS-BIOTIN 放射性标记 生物分布 177 Lu DTPA-BIS-BIOTIN label biodistribution
  • 相关文献

参考文献13

  • 1Lesch H P,Kaikkonen M U,Pikkarainen J T,et al.Avidin-Biotin Technology in Targeted Therapy[J].Expert Opin Drug Deliv,2010,7(5):551-564.
  • 2Boerman O C,van Schaijk F G,Oyen W J G,et al.Pretargeted Radioimmunotherapy of Cancer:Progress Step by Step[J].J Nucl Med,2003,44:400-411.
  • 3Stella M,de Nardi P,Paganelli G,et al.Avidin-Biotin System in Radio Immunoguided Surgery for Colorectal Cancer,Advantages and Limits[J].Dis Colon Rectum,1994,37:335.
  • 4Sharkey R M,Karacay H,Cardillo T M,et al.Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods[J].Clin Cancer Res,2005(11):7 109s-7 121s.
  • 5Goodwin D A,Meares C F.Pretargeted Peptide Imaging and Therapy[J].Cancer Biother Radiopharm,1999,14:145-152.
  • 6Goldenberg D M.Targeted Therapy of Cancer With Radiolaleled Antibodies[J].J Nucl Med,2002,43:693-713.
  • 7Rosebrough S F,Hartley D F.Biochemical Modification of Streptavidin and Avidin:in Vitro and in Vivo Analysis[J].J Nucl Med,1996,37(8):1 380-1 384.
  • 8Meredith R F,Buchsbaum D J.Pretargeted Radioimmunotherapy[J].Int J Radiation Ontology Biol Phys,2006,66:S57-S59.
  • 9Graves S S,Dearstyne E,Lin Y,et al.Combination Therapy With Pretarget CC49 Radioimmunotherapy and Gerneitabine Prolongs Tumor Doubling Time in Amurine Xenograftmod Elofcolon Cancermore Effectively Than Either Monotherapy[J].Clin Cancer Res,2003,9(10 Pt 1):3 712-3 721.
  • 10Gasparri A,Moro M,Curnis F,et al.Tumor Pretargeting With Avidin Improves the Therapeutic Index of Biotinylated Tumor Necrosis Factor α in Mouse Model[J].Cancer Research,1999,59:2 917-2 923.

同被引文献21

  • 1崔海平,翟士桢,杜进.生长抑素-葡聚糖的^(99)Tc^m标记及体外结合分析[J].同位素,2006,19(2):83-86. 被引量:6
  • 2何川,翟士桢,杜进,戴皓洁,罗莎.^(99)Tc^m标记的新型糖基化生长抑素生物学评价[J].同位素,2007,20(1):11-15. 被引量:1
  • 3翟士桢,杜进,沈亦佳,胡春林,何川,赵磊.糖基化生长抑素^(90)Y标记及体内外生物学评价[J].核技术,2007,30(5):454-458. 被引量:1
  • 4何川,翟士桢,杜进.新型糖基化生长抑素的合成及^(99)Tc^m标记[J].核化学与放射化学,2007,29(3):178-183. 被引量:2
  • 5Sharkey RM, Karacay H, Cardillo TM, et al. Imp roving the delivery of radionuelides for imaging and therapy of cancer using p retargeting methods[J]. Clin Cancer Res , 2005, 11(S): 7 109-7 121.
  • 6Mel Ton RG, Wibl In CN, Foster RL, et al. Covalent linkage of carboxypeptidase G2 to soluble dextrans: properties of conjugates and effect s on plasma persistence in mice[J]. Biochem Pharm, 1987, 36: 105-112.
  • 7Anthony LB, Woltering EA, Espanan GD, et al. Indium-111-pentetreotide prolongs survival in gastroenteropanereatic malignancies [J]. Seminars Nucl Med, 2002, 32: 123-132.
  • 8Manabe Y, Tsubota T, Haruta Y, et al. Production of a monoclonal antibody-methotrexate conjugate utilizing dextran T-40 and its biologic activity [J]. J Lab Clin Med, 1984, 104: 445-454.
  • 9Behe M, Du J, Becker W, et al. Biodist ribution, blood half-life and receptor binding of a somatostatin dextran conjugate [J]. Medical Oncology, 2001, 18: 59-64.
  • 10Wulbrand U, Feldman M, Pfestroffa, et al. A novel somatostatin conjugates with a high affinity to all five somatostatin receptor subtypes [J]. Cancer, 2002, 94 ($4): 1 293-1 297.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部